Du är här


OSE Pharma Group: OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015

September 29th, 2015, 5:45 pm - OSE Pharma SA
(ISIN : FR0012127173 ; Mnemo : OSE), an immuno-oncology biotech company
developing a T specific immunotherapy at
late clinical stage, announces its participation to the Large&Midcap Event to
be held on October 7 and 8 in Paris' Palais Brongniart.

By participating to this event dedicated to European midcaps, OSE Pharma will
specify its ambitions in the immuno-oncology area through the steps taken as
part of its promising clinical results and its international clinical phase 3
study. The company intends to play a leading role in two priority areas
through the development of Tedopi®, its flagship product: firstly, in
monotherapy for lung cancer and secondly, through therapeutic combinations,
an area where clear clinical findings are also expected.

"We are very pleased to participate to this edition of the Large&Midcap Event,
a first for OSE Pharma, following our recent IPO. This forum gives us an
opportunity to meet with European investors, all very interested in this
revolutionary approach and paradigm shift that immunotherapy is causing in
cancer care and where clinical results become a reality for patients",
said Dominique Costantini, CEO of OSE Pharma.


OSE Pharma is a European cancer immunotherapy company with a multi-epitope
technology named Memopi® that directs the body's immune system to generate a
specific cytotoxic T response to prevent cancer cell growth.

OSE Pharma's lead product, Tedopi®, combines 10 "neo-epitopes" directed
against five tumour associated antigens. In its most advanced application it
is about to enter a pivotal Phase III study in patients with advanced
non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed
first line therapy. Tedopi® has orphan drug status in the USA and is
considered as personalised medicine in Europe in HLA-A2 positive patients.

Furthermore, Tedopi® (OSE-2101) can be developed in Phase 2 in combination
with other immunotherapy treatments or targeted therapy.

It is also considered in other oncology indications, also with HLA-A2 positive
patients (ovaries, colon, prostate, breast).

Tedopi® targets five tumour associated antigens (TAA), selected because their
presence is linked to a poor prognosis and the severity of various cancers.
Tedopi® contains a total of ten optimised epitopes, or "neo- epitopes",
designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong
specific T cytotoxic responses that fight cancer and prevent tumour escape.

OSE Pharma is listed on Euronext Paris(ISIN : FR0012127173 ; Mnemo : OSE).
More information onwww.osepharma.com

Follow us on Twitter @OSE_Pharma

Press contacts

| OSE Pharma sa Citigate Dewe Rogerson |
| |
|Dominique Costantini, CEO |
|dominique.costantini@osepharma.com Laurence Bault / Lucie Larguier |
| +33 1 53 32 84 78 |
|Mob +33 6 13 20 77 49 laurence.bault@citigate.fr |
| |
|Alexis Peyroles, CFO |
|Alexis.peyroles@osepharma.com Alize RP |
| |
|Mob : +33 6 11 51 19 77 Florence Portejoie |
| |
| +33 6 47 38 90 04 |
| |
| fportejoie@alizerp.com |

This press release may expressly or implicitly contain forward-looking
statements relating to OSE Pharma and its activity. Although OSE Pharma's
management believes that the expectations reflected in these forward-looking
statements are reasonable, investors are cautioned that such statements are
related to known or unknown risks, uncertainties and other factors that could
lead actual results, financial conditions, performance or achievements to
differ materially from OSE Pharma's results, financial conditions,
performance or achievements expressed, projected or implied by such
information and forward-looking statements.
Other than as required by applicable law (article 223-1 et seq of the General
Regulation of the AMF), OSE Pharma issues this press release at the date
hereof and does not undertake any obligation to update or revise any
forward-looking information or statements.
These risks and uncertainties include among other things, the uncertainties
inherent in future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
For a description of risks and uncertainties which could lead to discrepancies
between actual results, financial condition, performance or achievements and
those contained in the forward-looking statements, please refer to Chapter 4
"Risk Factors" of the company's Documents de Base filed with the AMF under
number I. 14-056 on September, 17th 2014 and Chapter 2 "Risk Factors related
to the Offer" in the prospectus approved by the AMF under number 15-078 on
6th March 2015, which can be found on the websites of the AMF
(www.amf-france.org) and of OSE Pharma (www.osepharma.com).

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OSE Pharma Group via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.